Re-do parathyroid surgery, also known as remedial or re-operative parathyroid surgery, is one of the most challenging aspects of managing parathyroid disease. It is defined as a subsequent operation to treat parathyroid disease, most often primary hyperparathyroidism, usually after the first operation has failed to achieve cure.
Most of the patients who are evaluated for re-do parathyroid surgery at UCLA have had one failed parathyroid surgery which was performed elsewhere. We also commonly see patients who have had two failed prior operations, and the highest number of prior failed operations we have seen in one patient has been seven.
Most patients with a history of prior failed parathyroid surgery can be cured with a re-do parathyroid operation. However, we must qualify this statement by adding that the risks of re-do parathyroid surgery are higher than that of initial surgery, and that re-do parathyroid surgery should only be performed in expert centers (there are only a handful of qualified centers in the nation). Indeed, most surgeons practicing outside of expert parathyroid surgery centers are (wisely) unwilling to perform re-do parathyroid surgery given its significant challenges.
Unfortunately, quite often. Depending largely on surgeon experience, initial parathyroid surgery is unsuccessful in 1-30% of patients (see Parathyroid surgery success). As a result, we evaluate several patients in need of re-do parathyroid surgery every week and dedicate one full day per week to operating on patients who need re-do neck operations of various types. This work is laborious and fraught with risk. To state the obvious, it is highly preferable for patients to avoid the need for re-do parathyroid surgery altogether by having things done properly the first time. We will come back to this important theme later on.
Through our research, we have learned that only a small fraction (about 10%) of patients with failed initial parathyroid surgery ever undergo re-do surgery. For reasons that we do not fully understand, the majority of patients who are not cured during initial surgery are left to suffer the adverse health effects of primary hyperparathyroidism for the rest of their lives. Health problems associated with primary hyperparathyroidism include kidney stones, osteoporosis, abdominal pain, musculoskeletal pain, and fatigue (see Parathyroid surgery benefits). When UCLA Endocrine Surgery was established in 2006, we soon discovered that many local endocrinology practices were burdened with literally dozens of patients who had had failed parathyroid surgery. This motivated us to develop specific expertise and dedicated resources for this challenging group of patients. Over time, UCLA has become a destination medical center for patients who require re-do neck surgery; our patients come from throughout the Southern California metropolitan area, across the nation, and from overseas (see Distance surgery program).
The reasons behind failed parathyroid surgery are complex, but the leading cause is surgeon inexperience. Our research has shown that, in order to achieve good outcomes, a surgeon should perform at least one parathyroid operation per month. In order to achieve superior outcomes, a surgeon should perform at least one parathyroid operation per week (see Parathyroid surgery success). At UCLA, we typically perform 8 parathyroid operations per day. The most common explanation for failed initial parathyroid surgery is missed adenoma, i.e. the surgeon was unable to locate the single abnormal parathyroid gland responsible for the patient's high blood calcium level. Less commonly, failed surgery may arise when the surgeon only removes one gland in a patient who has multiple abnormal parathyroid glands (missed double adenoma or missed hyperplasia).
Recurrent hyperparathyroidism is defined by the re-appearance of high blood calcium levels more than 6 months after successful initial surgery for primary hyperparathyroidism. Potential causes of recurrent hyperparathyroidism are:
The best candidate for re-do parathyroid surgery is a patient who (A) has severe or symptomatic primary hyperparathyroidism, and (B) has a clear target on imaging. This gets to the key question when planning any operation: What is the balance of risk and benefit? Patients with severe hyperparathyroidism (blood calcium level >11.5 mg/dL) and those with symptoms such as kidney stones, loss of kidney function, and osteoporosis have a strong motivation to pursue additional surgery. In other words, they have a lot to gain from being cured. We frequently will re-operate on patients with less severe disease, but this requires careful discussion between the patient, surgeon, and often the patient's endocrinologist.
When considering re-do parathyroid surgery, a clear target (or targets) on imaging is essential. Why? During initial (first time) parathyroid surgery, the surgeon is able to move freely within the neck - healthy, previously untouched tissues are laid down in planes that separate easily during surgery and clearly show the underlying anatomy. During re-operation, scar tissue from initial surgery is present (to varying degrees) and makes dissection difficult. The surgeon is much less free to move around the neck; therefore, the best operation is an abbreviated one that focuses on a single known target or, in the uncommon case of missed hyperplasia, multiple targets.
Re-do parathyroid surgery is risky. Don't let anyone tell you otherwise. The risks are two to five times greater than for initial surgery. These risks include permanent hoarseness and failed surgery. In experienced hands, the risk of permanent hoarseness (recurrent laryngeal nerve injury) during initial parathyroid surgery should be less than 1 in 200. In re-do parathyroid surgery, the risk is 1-3%. Also, the second operation may not be successful. The success rate of initial parathyroid surgery by an expert surgeon is about 98%. The success rate of re-do parathyroid surgery by an expert surgeon is 80-95%.
To a significant degree, re-do parathyroid surgery is driven by the presence of a clear anatomic target. Since 2012, UCLA Endocrine Surgery has employed parathyroid 4-D CT in the planning of all reoperations for primary hyperparathyroidism. [see video on parathyroid 4-D CT]. 4D-CT provides the highest possible anatomic detail and affords the highest likelihood of achieving a safe and successful second operation.
For us, 4D-CT technology has been a "game changer," enabling >95% of patients with failed initial operations to become eligible for reoperation, greatly aiding our ability to counsel patients on surgical strategy, and allowing us to complete reoperations in a much shorter time. Many patients are understandably disappointed and wary after their first parathyroid operation has failed. 4D-CT allows us to sit down with the patient and walk through a series of high-resolution images so that the patient and their family can get a clear understanding of the surgical plan.
Re-do parathyroid surgery must be carefully planned. One should never rush into this type of operation, given its risks. We often meet patients who were rushed into a second operation elsewhere (sometimes only a day or two after initial surgery), and these reoperations almost universally fail. Planning for re-do parathyroid surgery involves a combination of detective work (analyzing what was done before) and assessing the patient's current state through laboratory testing (blood and sometimes urine) and imaging. We routinely request all prior operation reports, lab reports, pathology reports, and imaging reports. Also, we will request that all tissue samples (pathology slides) be sent to UCLA for re-analysis. The goal here is to question all the information associated with the first (failed) operation. Something clearly went wrong during initial surgery, and this is our chance to figure out what that was. This step of the process takes time, often several weeks while we work behind the scenes to scrutinize all of the records and microscopically analyze all of the tissues that were previously removed. Then, laboratory testing gives us information on the current severity of the patient's hyperparathyroidism. The last piece is imaging: 4D-CT is the cornerstone as you already know, and sometimes further imaging is required.
Re-do parathyroid surgery should only be attempted by high-volume centers that specialize in parathyroid surgery. Only a small number of qualified centers exist.
1: Sho S, Yilma M, Yeh MW, Livhits M, Wu JX, Hoang JK, Sepahdari AR. Prospective Validation of Two 4D-CT-Based Scoring Systems for Prediction of Multigland Disease in Primary Hyperparathyroidism. AJNR Am J Neuroradiol. 2016 Sep 22. [Epub ahead of print] PubMed PMID: 27659191.
2: Young S, Wu JX, Li N, Yeh MW, Livhits MJ. More Extensive Surgery May Not Improve Survival Over Parathyroidectomy Alone in Parathyroid Carcinoma. Ann Surg Oncol. 2016 Sep;23(9):2898-904. doi: 10.1245/s10434-016-5256-6. PubMed PMID: 27177488.
3: Yeh MW, Zhou H, Adams AL, Ituarte PH, Li N, Liu IL, Haigh PI. The Relationship of Parathyroidectomy and Bisphosphonates With Fracture Risk in Primary Hyperparathyroidism: An Observational Study. Ann Intern Med. 2016 Jun 7;164(11):715-23. doi: 10.7326/M15-1232. PubMed PMID: 27043778.
4: Wu JX, Yeh MW. Asymptomatic Primary Hyperparathyroidism: Diagnostic Pitfalls and Surgical Intervention. Surg Oncol Clin N Am. 2016 Jan;25(1):77-90. doi: 10.1016/j.soc.2015.08.004. Review. PubMed PMID: 26610775.
5: Cham S, Sepahdari AR, Hall KE, Yeh MW, Harari A. Dynamic Parathyroid Computed Tomography (4DCT) Facilitates Reoperative Parathyroidectomy and Enables Cure of Missed Hyperplasia. Ann Surg Oncol. 2015 Oct;22(11):3537-42. doi: 10.1245/s10434-014-4331-0. PubMed PMID: 25691276.
6: Abdulla AG, Ituarte PH, Harari A, Wu JX, Yeh MW. Trends in the frequency and quality of parathyroid surgery: analysis of 17,082 cases over 10 years. Ann Surg. 2015 Apr;261(4):746-50. doi: 10.1097/SLA.0000000000000812. PubMed PMID: 24950283.
7: Edling KL, Korenman SG, Janzen C, Sohsman MY, Apple SK, Bhuta S, Yeh MW. A pregnant dilemma: primary hyperparathyroidism due to parathyromatosis in pregnancy. Endocr Pract. 2014 Feb;20(2):e14-7. doi: 10.4158/EP13105.CR. PubMed PMID: 24013984.
8: Abdulla AG, O'Leary EM, Isorena JP, Diaz MF, Yeh MW. Recurrent hyperparathyroidism and a novel nonsense mutation in a patient with hyperparathyroidism-jaw tumor syndrome. Endocr Pract. 2013 Nov-Dec;19(6):e134-7. doi: 10.4158/EP13187.CR. PubMed PMID: 23757631.
9: Morris LF, Loh C, Ro K, Wiseman JE, Gomes AS, Asandra A, Wariri S, Yeh MW. Non-super-selective venous sampling for persistent hyperparathyroidism using a systemic hypocalcemic challenge. J Vasc Interv Radiol. 2012 Sep;23(9):1191-9. doi: 10.1016/j.jvir.2012.06.005. PubMed PMID: 22832137.
10: Yeh MW, Wiseman JE, Ituarte PH, Pasternak JD, Hwang RS, Wu B, Liu IL, Haigh PI. Surgery for primary hyperparathyroidism: are the consensus guidelines being followed? Ann Surg. 2012 Jun;255(6):1179-83. doi: 10.1097/SLA.0b013e31824dad7d. PubMed PMID: 22584631.
11: Yeh MW, Wiseman JE, Chu SD, Ituarte PH, Liu IL, Young KL, Kang SJ, Harari A, Haigh PI. Population-level predictors of persistent hyperparathyroidism. Surgery. 2011 Dec;150(6):1113-9. doi: 10.1016/j.surg.2011.09.025. PubMed PMID: 22136829.
12: Hong JC, Morris LF, Park EJ, Ituarte PH, Lee CH, Yeh MW. Transient increases in intraoperative parathyroid levels related to anesthetic technique. Surgery. 2011 Dec;150(6):1069-75. doi: 10.1016/j.surg.2011.09.008. PubMed PMID: 22136823.
13: Nguyen J, Lau O, Abemayor E, Yeh MW. Undescended parathyroid adenoma arising within the hypoglossal nerve. Arch Otolaryngol Head Neck Surg. 2011 Jul;137(7):709-11. doi: 10.1001/archoto.2011.90. PubMed PMID: 21768418.
14: Levin O, Morris LF, Wah DT, Butch AW, Yeh MW. Falsely elevated plasma parathyroid hormone level mimicking tertiary hyperparathyroidism. Endocr Pract. 2011 Mar-Apr;17(2):e8-11. doi: 10.4158/EP10235.CR. Review. PubMed PMID: 21247852.
15: Morris LF, Zelada J, Wu B, Hahn TJ, Yeh MW. Parathyroid surgery in the
elderly. Oncologist. 2010;15(12):1273-84. doi: 10.1634/theoncologist.2010-0158.
PubMed PMID: 21159725; PubMed Central PMCID: PMC3227933.
16: Kulkarni RP, Ituarte PH, Gunderson D, Yeh MW. Clinical pathways improve hospital resource use in endocrine surgery. J Am Coll Surg. 2011 Jan;212(1):35-41. doi: 10.1016/j.jamcollsurg.2010.09.016. PubMed PMID: 21123093.
17: Wu B, Haigh PI, Hwang R, Ituarte PH, Liu IL, Hahn TJ, Yeh MW. Underutilization of parathyroidectomy in elderly patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2010 Sep;95(9):4324-30. doi: 10.1210/jc.2009-2819. PubMed PMID: 20610600; PubMed Central PMCID: PMC2936062.
18: Hwang RS, Morris LF, Ro K, Park S, Ituarte PH, Hong JC, Yeh MW. A selective, Bayesian approach to intraoperative PTH monitoring. Ann Surg. 2010 Jun;251(6):1122-6. doi: 10.1097/SLA.0b013e3181dd4ee1. PubMed PMID: 20485138.
19: Morris LF, Zanocco K, Ituarte PH, Ro K, Duh QY, Sturgeon C, Yeh MW. The value of intraoperative parathyroid hormone monitoring in localized primary hyperparathyroidism: a cost analysis. Ann Surg Oncol. 2010 Mar;17(3):679-85. doi: 10.1245/s10434-009-0773-1. PubMed PMID: 19885701; PubMed Central PMCID: PMC2820694.